<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486016</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00059884</org_study_id>
    <nct_id>NCT02486016</nct_id>
  </id_info>
  <brief_title>Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl TDSs in Healthy Adults</brief_title>
  <official_title>Determination of Serum Fentanyl Levels After Using Reference and Generic Transdermal Fentanyl TDSs With and Without Standardized Heat Application in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Open-label, Non-Randomized, 3-way Crossover Bioequivalence Study to compare
      fentanyl release after heating of a brand name (Duragesic) and generic (Apotex and Mylan)
      fentanyl (transdermal delivery system)TDSs in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is intended to determine the effect of heat on FDA-approved fentanyl TDSs
      and whether the heat applied will result in more fentanyl being absorbed through the skin
      than without applying heat. This is important given that little is known about how the
      release of fentanyl is affected by heat, particularly for generic products. This study will
      use fentanyl TDSs (brand name and generic TDSs) that have been approved by the Food and Drug
      Administration (FDA) and are already prescribed to customers in the United States, and will
      not include any placebos.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2015</start_date>
  <completion_date type="Actual">August 9, 2017</completion_date>
  <primary_completion_date type="Actual">August 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial Area Under the Curve (AUC) Attained With Early and Late Heat in Each of the Three Fentanyl TDSs (Reference and Generic)</measure>
    <time_frame>six procedure days for each participant</time_frame>
    <description>Partial area under the flux-time curve of fentanyl calculated from 11 to 14 h for Early Heat and 18 to 21 h for Late Heat study designs
Blood samples obtained at 15 min prior to patch application [baseline], and at 1:00, 10:00, 10:55, 11:05, 11:15, 11:25, 11:35, 11:45, 12:00, 13:00, 14:00, 16:00, 17:00, 17:55, 18:05, 18:15, 18:25, 18:35, 18:45, 19:00, 20:00, 21:00, and 22:00 h post-patch application</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Peer Review, Research</condition>
  <arm_group>
    <arm_group_label>Duragesic Reference Fentanyl TDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apotex Generic Fentanyl TDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mylan Generic Fentanyl TDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duragesic reference fentanyl TDS</intervention_name>
    <description>25 µg/hour</description>
    <arm_group_label>Duragesic Reference Fentanyl TDS</arm_group_label>
    <other_name>Brand name fentanyl TDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apotex generic fentanyl TDS</intervention_name>
    <description>25 µg/hour</description>
    <arm_group_label>Apotex Generic Fentanyl TDS</arm_group_label>
    <other_name>Generic fentanyl TDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mylan generic fentanyl TDS</intervention_name>
    <description>25 µg/hour</description>
    <arm_group_label>Mylan Generic Fentanyl TDS</arm_group_label>
    <other_name>Generic fentanyl TDS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Men or non-pregnant women of any ethnic background between the age of 18 and 45
             years old.

          -  2. Subjects must be non-smokers (must have refrained from the use of
             nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars,
             chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and
             are not currently using tobacco products.

          -  3. Provide written informed consent before initiation of any study procedures.

          -  4. Available for follow-up for the planned duration of the study.

          -  5. Able to communicate well with the investigators.

          -  6. Able to adhere to the study protocol schedule.

          -  7. Subjects who are within their ideal body weight (BMI&gt;17 and ≤ 28).

          -  8. Demonstrate comprehension of the protocol procedures and knowledge of study by
             passing (&gt;70% correct responses) a written examination containing 20 multiple choice
             and true false questions covering all aspects of the study including the purpose,
             procedures, risks and benefits.

          -  9. Subjects deemed to be healthy as judged by the Medically Accountable Investigator
             (MAI) and determined by medical history, physical examination, and medication history.

          -  10. Negative urine drug screening test.

          -  11. Have a normal blood pressure (systolic: 90-140 mmHg; diastolic: 50-90 mmHg) and
             heart rate (55-100 bpm).

          -  12. Have normal screening laboratories for WBC, Hgb, platelets, sodium, potassium,
             chloride, bicarbonate, BUN, creatinine, ALT, AST and total bilirubin.

          -  13. Have normal screening laboratories for urine protein and urine glucose.

          -  14. Female subjects must be of non-childbearing potential (as defined as surgically
             sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more
             than 1 year), or if of childbearing potential must be non-pregnant at the time of
             enrollment and on the morning of each procedure, and must agree to use hormonal or
             barrier birth control such as implants, injectables, combined oral contraceptives,
             some intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner.

          -  15. Agrees not to participate in another clinical study during the study period.

          -  16. Agrees not to donate blood to a blood bank throughout participation in the study
             and for at least 3 months after last procedure day.

          -  17. Have a normal ECG.

        Exclusion Criteria:

          -  1. Women who are pregnant, lactating, breast feeding or have a positive serum
             pregnancy test at enrollment or on the morning of any procedure day.

          -  2. Smokers (current use or use over the previous 2 months of nicotine-containing
             substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco,
             gum, patch or electronic cigarettes).

          -  3. Participation in any ongoing investigational drug trial or clinical drug trial.

          -  4. Abnormal Vital signs, defined as:

               -  Hypertension (systolic blood pressure &gt;140 mm Hg or diastolic blood pressure &gt;90
                  mm Hg) at rest on 2 separate days)

               -  Heart rate &lt;55 at rest on 2 separate days

               -  Respiratory rate &gt;20

          -  5. Temperature &gt; 38.0°C (100.4°F) or symptoms of an acute self-limited illness such as
             an upper respiratory infection or gastroenteritis within 7 days of application of the
             fentanyl TDS.

          -  6. History of chronic obstructive pulmonary disease.

          -  7. Active positive Hepatitis B, C, and HIV serologies.

          -  8. Positive urine drug screening test.

          -  9. Use of any prescription medication during the period 0 to 30 days or over-the
             counter medication (vitamin, herbal supplements and birth control medications not
             included) during the period 0 to 3 days before entry to the study.

          -  10. Donation or loss of greater than one pint of blood within 60 days of entry to the
             study.

          -  11. Any prior serious adverse reaction or hypersensitivity to fentanyl, naltrexone or
             naloxone or any of the inactive ingredients in the TDS (alcohol, ethylene vinyl
             acetate-copolymer membrane and hydroxyethyl cellulose, polyester, silicone adhesive,
             isopropyl myristate, octyldodecanol, polybutene, polyisobutene, dimethicone NF, or
             polyolefin).

          -  12. Have a diagnosis of schizophrenia or other major psychiatric diagnosis or mental
             illness (e.g. major depression).

          -  13. Received an experimental agent (vaccine, drug, biologic, device, blood product or
             medication) within 1 month before enrollment in this study or expects to receive an
             experimental agent during the study.

          -  14. Any condition that would, in the opinion of the Medically Accountable Investigator
             (MAI), place the subject at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol.

          -  15. Inability to communicate or co-operate with the investigators.

          -  16. History of consumption of alcohol within 24 hours prior to dose administration.

          -  17. Within 72 hours prior to dosing, use of antihistamines or use of topical drugs at
             TDS site.

          -  18. Subject has an obvious difference in skin color between arms or the presence of a
             skin condition, open sore, scar tissue, tattoo, or coloration that would interfere
             with placement of test articles, skin assessment, or reactions to drug.

          -  19. Use of monoamine oxidase inhibitors 21 days prior to study.

          -  20. Failure to pass opioid dependence challenge test on each procedure day before
             application of the fentanyl TDS. Each subject will be injected subcutaneously with
             naloxone HCl (0.8 mg injection) and will be observed for 45 minutes for signs and
             symptoms of opioid withdrawal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audra Stinchcomb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore Center for Vaccine Development</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <results_first_submitted>August 10, 2018</results_first_submitted>
  <results_first_submitted_qc>August 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2019</results_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Audra Stinchcomb</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Therapeutic Equivalency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>AAPS presented poster</doc_type>
      <doc_url>https://www.aaps.org/search?executeSearch=true&amp;SearchTerm=published+posters&amp;l=1</doc_url>
      <doc_comment>Shin SH, Yu M, Thomas S, Hammell DC, Ghosh, P, Raney SG, Hassan HH, Stinchcomb AL. Evaluation of level A in vitro/in vivo correlations (IVIVC) for nicotine and fentanyl transdermal delivery systems with transient heat exposure by using multiple approaches. Poster presentation at the 2017 AAPS Annual Meeting and Exposition; November 12-15, 2017; San Diego, CA</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Stat Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02486016/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Stat Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02486016/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fentanyl TDS</title>
          <description>Each volunteer participates in six procedure days. 1) Apotex generic fentanyl TDS (25 µg/h) with heat applied at 11 h for one hour 2) Apotex generic fentanyl TDS (25 µg/h) with heat at 18 h for one hour 3) Duragesic fentanyl TDS (25 µg/h) with heat applied at 11 h for one hour 4) Duragesic fentanyl TDS (25 µg/h) with heat at 18 h for one hour 5) Mylan generic fentanyl TDS (25 µg/h) with heat applied at 11 h for one hour 6) Mylan generic fentanyl TDS (25 µg/h) with heat at 18 h for one hour
Two week wash out period between each procedure day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">Same 10 volunteers completed Apotex, Duragesic and Mylan arms of the study; crossover study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Same 10 volunteers used for all arms of the study; crossover study. The 10 volunteers were their own baselines.</population>
      <group_list>
        <group group_id="B1">
          <title>Fentanyl TDS</title>
          <description>Each volunteer participates in six procedure days.
Apotex generic fentanyl TDS (25 µg/h) with heat applied at 11 h for one hour
Apotex generic fentanyl TDS (25 µg/h) with heat at 18 h for one hour
Duragesic fentanyl TDS (25 µg/h) with heat applied at 11 h for one hour
Duragesic fentanyl TDS (25 µg/h) with heat at 18 h for one hour
Mylan generic fentanyl TDS (25 µg/h) with heat applied at 11 h for one hour
Mylan generic fentanyl TDS (25 µg/h) with heat at 18 h for one hour
Two week wash out period between each procedure day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Partial Area Under the Curve (AUC) Attained With Early and Late Heat in Each of the Three Fentanyl TDSs (Reference and Generic)</title>
        <description>Partial area under the flux-time curve of fentanyl calculated from 11 to 14 h for Early Heat and 18 to 21 h for Late Heat study designs
Blood samples obtained at 15 min prior to patch application [baseline], and at 1:00, 10:00, 10:55, 11:05, 11:15, 11:25, 11:35, 11:45, 12:00, 13:00, 14:00, 16:00, 17:00, 17:55, 18:05, 18:15, 18:25, 18:35, 18:45, 19:00, 20:00, 21:00, and 22:00 h post-patch application</description>
        <time_frame>six procedure days for each participant</time_frame>
        <population>Partial area under the flux-time curve of fentanyl from 11 to 14 h for Early Heat and 18 to 21 h for Late Heat study designs. Each was corrected to account for different TDS sizes. Comparison was early heat to late heat differences.</population>
        <group_list>
          <group group_id="O1">
            <title>Apotex Generic Fentanyl TDS</title>
            <description>Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
Apotex generic fentanyl TDS: 25 µg/hour</description>
          </group>
          <group group_id="O2">
            <title>Duragesic Reference Fentanyl TDS</title>
            <description>Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
Duragesic reference fentanyl TDS: 25 µg/hour</description>
          </group>
          <group group_id="O3">
            <title>Mylan Generic Fentanyl TDS</title>
            <description>Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
Mylan generic fentanyl TDS: 25 µg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Area Under the Curve (AUC) Attained With Early and Late Heat in Each of the Three Fentanyl TDSs (Reference and Generic)</title>
          <description>Partial area under the flux-time curve of fentanyl calculated from 11 to 14 h for Early Heat and 18 to 21 h for Late Heat study designs
Blood samples obtained at 15 min prior to patch application [baseline], and at 1:00, 10:00, 10:55, 11:05, 11:15, 11:25, 11:35, 11:45, 12:00, 13:00, 14:00, 16:00, 17:00, 17:55, 18:05, 18:15, 18:25, 18:35, 18:45, 19:00, 20:00, 21:00, and 22:00 h post-patch application</description>
          <population>Partial area under the flux-time curve of fentanyl from 11 to 14 h for Early Heat and 18 to 21 h for Late Heat study designs. Each was corrected to account for different TDS sizes. Comparison was early heat to late heat differences.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early Heat (11 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.4"/>
                    <measurement group_id="O2" value="1.7" spread="1.4"/>
                    <measurement group_id="O3" value="2.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late Heat (18 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.4"/>
                    <measurement group_id="O2" value="2.4" spread="1.0"/>
                    <measurement group_id="O3" value="2.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Minimum 19 weeks; the period of time was dependent on how long it took the volunteer to complete six procedure days with a minimum of 2 weeks washout between procedure days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apotex Generic Fentanyl TDS</title>
          <description>Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
Apotex generic fentanyl TDS: 25 µg/hour</description>
        </group>
        <group group_id="E2">
          <title>Duragesic Reference Fentanyl TDS</title>
          <description>Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
Duragesic reference fentanyl TDS: 25 µg/hour</description>
        </group>
        <group group_id="E3">
          <title>Mylan Generic Fentanyl TDS</title>
          <description>Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
Mylan generic fentanyl TDS: 25 µg/hour</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Increased blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased respiratory rate</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Increased respiratory rate</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Audra Stinchomb (PI)</name_or_title>
      <organization>University of Maryland, Baltimore School of Pharmacy</organization>
      <phone>410-706-2646</phone>
      <email>astinchc@rx.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

